Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Checked against the public recordLast updated Mar 5, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- University of Louisville
- Interventions being studied
- Drug: zoledronic acid
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * invasive lung cancer (small cell or non-small cell lung cancer) * osteolytic bone metastasis determined by clinical exam, bone scan/XR * age \> 18 years Exclusion Criteria: * concurrent malignancy with a second primary * renal failure (serum creatinine \> 3mg/dl) * pregnancy * active rheumatoid arthritis * intolerance to zoledronic acid
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- James Graham Brown Cancer CenterLouisville, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2018. Always confirm current availability with the study team.